Dabrafenib 50mg and 75mg patent novartis?

It sounds like you’re asking about dosing strength options (50 mg and 75 mg) of dabrafenib and whether Novartis has the patent for those strengths.

1) Dabrafenib strengths (50 mg / 75 mg)

Dabrafenib is commonly marketed in capsule strengths such as 50 mg and 75 mg (brand products have been available in these strengths depending on country/market).

2) Is the patent held by Novartis?

Typically, dabrafenib was originally developed by Novartis and associated patents were filed by/through the Novartis entity that owns the original drug development IP.
However, whether Novartis still holds a valid patent today depends on:

• the country (patent status varies by jurisdiction),
• the type of patent (composition of matter, formulation, method of use, etc.),
• the expiration date and any extensions (and regulatory exclusivities like SPCs).

Quick question (so I can answer precisely)

Which country/region are you asking about (e.g., US, EU, UK, India, Canada)—and do you mean patent for:

1. dabrafenib itself, or
2. the 50 mg / 75 mg capsule formulations specifically, or
3. method of use (e.g., melanoma/NSCLC indications)?

If you tell me the country and which of the above you mean, I can guide you to the correct patent/exclusivity angle.